Related Experiment Video

Updated: Jan 14, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.9K

[Advances in clinical pharmacotherapy for neonatal Ureaplasma urealyticum infection]

Bei-Bo Cai1, Fei-Fei Chen1, Fang Luo1

  • 1Department of Clinical Pharmacy, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics
|October 22, 2025
PubMed

Insights

Ureaplasma urealyticum (UU) in newborns can cause serious respiratory issues and developmental problems. This review explores safe and effective medication options for treating neonatal UU infections, as no standard treatment exists.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Ureaplasma urealyticum (UU) is a common pathogen in the neonatal respiratory tract.
  • Vertical transmission from mother to infant occurs regardless of membrane rupture or delivery mode.
  • UU infection is linked to preterm birth, low birth weight, bronchopulmonary dysplasia, and neurodevelopmental impairment.

Purpose of the Study:

  • To review current pharmacotherapeutic options for neonatal Ureaplasma urealyticum infections.
  • To provide guidance for clinical practice in managing neonatal UU infections.
  • To address the lack of a standardized treatment regimen.

Main Methods:

  • Literature review of existing studies on Ureaplasma urealyticum treatment in neonates.
  • Analysis of pharmacologic interventions, focusing on efficacy and safety profiles.
  • Synthesis of data to identify potential treatment strategies.

Main Results:

  • No unified standard regimen currently exists for neonatal UU infection treatment.
  • Various pharmacologic options are available, each with specific efficacy and safety considerations.
  • Balancing treatment efficacy with the immature neonatal immune and organ systems is crucial.

Conclusions:

  • Effective pharmacologic treatment for neonatal UU infection requires careful consideration of safety and efficacy.
  • Further research and consensus are needed to establish standardized treatment guidelines.
  • Informed clinical decision-making is essential for optimizing outcomes in affected neonates.

Keywords:
MacrolidesNeonateTherapyUreaplasma urealyticum

More Related Videos

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development08:50

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development

Published on: June 24, 2020

4.2K
Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice04:18

Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice

Published on: October 10, 2025

353

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
209
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
250
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
308
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
432
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
475
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
241